Akero Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview

Akero Therapeutics

10/05/2024 16:09

* Akero Therapeutics Inc  AKRO.OQ   AKRO.O  is expected
to show no
change in quarterly revenue when it reports  results on May 10
for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Akero Therapeutics Inc
is for
a loss of 97 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 5.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Akero
Therapeutics Inc is $50.00​, above​ its last closing price
of $20.80. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.96       -0.95      -0.90     Beat    5.5
 Dec. 31 2024  -0.91       -0.86      -0.99     Missed  -14.9
 Sep. 30 2023  -0.69       -0.68      -0.71     Missed  -4.2​
 Jun. 30 2023  -0.62       -0.63      -0.60     Beat    4.5
 ​​Mar.        -0.66       -0.67      -0.55     Beat    18.2
 31 2023                                                
 Dec. 31 2022  -0.81       -0.80      -0.49     Beat    38.6​
 Sep. 30 2022  -0.71       -0.74      -0.92     Missed  -24.7
 Jun. 30 2022  -0.79       -0.86      -0.77     Beat    10
 This summary was machine generated May 10 at 15:09 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)